- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03374267
Registry Platform Urologic Cancer (CARAT)
Clinical Research Platform On Urologic Cancer Treatment And Outcome (Registry Platform Urologic Cancer; CARAT)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
CARAT is a national, observational, prospective, longitudinal, multicenter cohort study (tumor registry platform) with the purpose to record information on the antineoplastic treatment of renal cell carcinoma and urothelial cancer in Germany. The registry will follow patients with advanced renal carcinoma for up to three years, and patients with advanced urothelial cancer for up to two years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented.
Health-related quality of life (HRQoL) in patients with renal cell carcinoma or urothelial cancel will be evaluated for up to two years.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Michaela Koska
- Phone Number: +49 761 15242-0
- Email: info@iomedico.de
Study Locations
-
-
-
Multiple Locations, Germany
- Recruiting
- Multiple sites, Germany
-
Contact:
- iOMEDICO AG
- Phone Number: +49 761 152420
- Email: info@iomedico.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Female and male patients with aRCC or aUBC (locally advanced, inoperable or metastatic)
- Patients at start of their first-line systemic treatment for aRCC or aUBC
Written informed consent
- Patients participating in the PRO module: signing of in-formed consent form and completion of baseline questionnaire before start of initial systemic treatment
- Patients not participating in the PRO module: within twelve weeks after start of systemic first-line for aRCC or aUBC
- Age ≥ 18 years
Exclusion Criteria:
- Patients with prior systemic therapy for aRCC or aUBC
- No systemic treatment for aRCC or aUBC
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
aUBC
Patients with advanced urothelial carcinoma
|
Physician's choice according to patient's needs.
|
aRCC
Patients with advanced renal cell carcinoma
|
Physician's choice according to patient's needs.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Course of treatment (treatment reality)
Time Frame: 3 years per patient
|
Documentation of anamnestic data and therapy sequences
|
3 years per patient
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Best Response
Time Frame: 3 years per patient
|
Documentation of response rates per line of treatment.
|
3 years per patient
|
Progression-free survival
Time Frame: 3 years per patient
|
Documentation of progression-free survival per line of treatment.
|
3 years per patient
|
Overall survival
Time Frame: 3 years per patient
|
Documentation of overall survival time.
|
3 years per patient
|
Health-related quality of life (Patient-reported outcome)
Time Frame: 2 years per patient
|
Cohort aRCC: National Comprehensive Cancer Network/ Functional Assessment of Cancer Therapy (FACT)-Kidney Symptom Index 19 (NCCN-FACT FKSI-19) Cohort aUBC: NCCN/FACT Bladder Symptom Index (NCCN-FACT FBlSI-18, Version 2)
|
2 years per patient
|
Treatment symptom related quality of life
Time Frame: 2 years per patient
|
Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™) - Items/Scores cohort aRCC: 3/7/15/22/24/27/28/50/51; Items/Scores cohort aUBC: 3/7/15/22/24/27/28/39/45/50/51
|
2 years per patient
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Michael Staehler, Prof. Dr., Urologische Klinik und Poliklinik, Klinikum der Universität München
- Study Chair: Peter Goebell, Prof. Dr., Urologische Universitätsklinik, Waldkrankenhaus St. Marien
- Study Chair: Lothar Müller, Dr., Onkologie Leer - Emden - Papenburg
- Study Chair: Viktor Grünwald, Prof. Dr., Universitätsklinikum Essen (AöR), Westdeutsches Tumorzentrum Essen
- Study Chair: Carsten Grüllich, Prof. Dr., Caritas Krankenhaus, Lebach
- Study Chair: Christian Gratzke, Prof. Dr., Universitätsklinikum Freiburg Urologie
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Kidney Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Carcinoma, Renal Cell
- Carcinoma
- Urologic Neoplasms
Other Study ID Numbers
- iOM-110363
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Cell Carcinoma
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
Australian and New Zealand Urogenital and Prostate...RecruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11.2 Translocation-Related Renal Cell CarcinomaAustralia
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell CarcinomaUnited States, Taiwan, Australia
-
Bradley A. McGregor, MDBristol-Myers Squibb; ExelixisRecruitingRenal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Collecting Duct Renal Cell Carcinoma | Translocation Renal Cell Carcinoma | Unresectable Advanced Renal Cell Carcinoma | Metastatic Ncc Renal Cell CarcinomaUnited States
-
Jonsson Comprehensive Cancer CenterBeiGene; Driven To CureWithdrawnMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Unresectable Renal Cell Carcinoma | Hereditary Leiomyomatosis and Renal Cell Carcinoma | Clear Cell Papillary Renal Neoplasm | Hereditary Papillary Renal Cell Carcinoma and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingChromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma | Fumarate Hydratase Deficient Renal Cell Carcinoma | Succinate Dehydrogenase Deficient Renal Cell Carcinoma | Collecting Duct Renal...United States
-
Australian and New Zealand Urogenital and Prostate...Bristol-Myers SquibbActive, not recruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11 Translocation CarcinomaAustralia
-
Peloton Therapeutics, Inc.Active, not recruitingKidney Cancer | Renal Cell Carcinoma | Renal Cancer | Renal Cell Carcinoma (RCC) | Renal Cell Cancer Metastatic | Kidney | Clear Cell Renal Cell Carcinoma (ccRCC) | Renal Cell Carcinoma Recurrent | Renal Cell Cancer, RecurrentUnited States
-
National Cancer Institute (NCI)Canadian Cancer Trials GroupActive, not recruitingUnresectable Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma | Metastatic Papillary Renal Cell Carcinoma | Locally Advanced Papillary Renal Cell CarcinomaUnited States, Canada
Clinical Trials on Routine care as per site standard.
-
iOMEDICO AGRecruitingChronic Lymphocytic Leukemia (CLL) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Marginal Zone Lymphoma (MZL) | Waldenström's Macroglobulinemia (WM)Germany
-
iOMEDICO AGRecruitingGastric Adenocarcinoma | Esophageal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Gastroesophageal Junction AdenocarcinomaGermany
-
iOMEDICO AGDeutsche Studiengruppe Multiples Myelom (DSMM)Recruiting
-
University of CalgaryAlberta Health servicesRecruiting
-
University Health Network, TorontoRecruitingHigh Grade GliomaCanada
-
Unity Health TorontoRoche Pharma AGCompletedDyspnea | Acute Heart Failure | Shortness of BreathCanada, United States, New Zealand
-
PfizerCompleted
-
McMaster UniversityUnknownColorectal CancerCanada
-
Samir SabaCompletedHeart Failure, Wide QRS ComplexUnited States